BOSTON, LAUSANNE, BORDEAUX, and MARSEILLE – FEBRUARY 1, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, have announced, in conjunction with Assises de Génétique, an extension of their partnership with Institut Paoli Calmettes (IPC), one of the 18 French Comprehensive Cancer Centers (CLCC), to further support the implementation, automatization, and accreditation of solid tumor tests, to include lung, breast, ovarian and onco-hematological cancers.
Recently named a Reference Medical Biology Laboratory, the oncogenetic laboratory of Institut Paoli Calmettes manages hereditary cancers and both solid tumor and myeloid/lymphoid hematologic malignancies. IPC employs 1,800 research, medical, and non-medical personnel with the goal of providing comprehensive care for every aspect of cancer treatment, including research, education, training, and medical and supportive care.